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Abstract
SMARCB1 is deleted in rhabdoid tumor, an aggressive paediatric malignancy affecting the kidney and CNS. We hypothesized
that the oncogenic pathway in rhabdoid tumors involved epigenetic silencing of key cell cycle regulators as a consequence
of altered chromatin-remodelling, attributable to loss of SMARCB1, and that this hypothesis if proven could provide a
biological rationale for testing epigenetic therapies in this disease. We used an inducible expression system to show that the
imprinted cell cycle inhibitor CDKN1C is a downstream target for SMARCB1 and is transcriptionally activated by increased
histone H3 and H4 acetylation at the promoter. We also show that CDKN1C expression induces cell cycle arrest, CDKN1C
knockdown with siRNA is associated with increased proliferation, and is able to compete against the anti-proliferative effect
of restored SMARCB1 expression. The histone deacetylase inhibitor (HDACi), Romidepsin, specifically restored CDKN1C
expression in rhabdoid tumor cells through promoter histone H3 and H4 acetylation, recapitulating the effect of SMARCB1
on CDKNIC allelic expression, and induced cell cycle arrest in G401 and STM91-01 rhabdoid tumor cell lines. CDKN1C
expression was also shown to be generally absent in clinical specimens of rhabdoid tumor, however CDKN1A and CDKN1B
expression persisted. Our observations suggest that maintenance of CDKN1C expression plays a critical role in preventing
rhabdoid tumor growth. Significantly, we report for the first time, parallels between the molecular pathways of SMARCB1
restoration and Romidepsin treatment, and demonstrate a biological basis for the further exploration of histone deacetylase
inhibitors as relevant therapeutic reagents in the treatment of rhabdoid tumor.
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Introduction
Rhabdoid tumor (RT) is an aggressive although rare tumor of
infancy and early childhood resistant to conventional chemother-
apies and radiotherapy. The majority of afflicted children
succumb to their disease within several months of diagnosis.
Rhabdoid tumors mainly arise in the kidney where they are known
as rhabdoid tumours and in the central nervous system where they
are referred to as Atypical Teratoid Rhabdoid Tumor (AT/RT).
They are characterized genetically by deletion or allelic loss of
chromosome 22q, and associated inactivating mutations or
deletion of the tumor suppressor gene SMARCB1 (OMIM
601607) [1,2,3,4,5,6].
Homozygous deletion of smarcb1 in mice is embryonic lethal,
however, heterozygous mice develop tumors that are histologically
similar to their human counterparts [7,8,9]. Tumor formation in
mice is accelerated by coincident p53 mutation[10] and it has been
recently proposed that tumor formation associated with loss of
SMARCB1 may arise due to permissive defects in cellular DNA
damage response pathways [11]. Although SMARCB1 deletion is
predominantly associated with RT, recently SMARCB1 inactiva-
tion and mutation has been described in epitheloid sarcoma and
familial schwannomatosis [12,13].
One suggested mechanism by which loss of SMARCB1 facilitates
oncogenesis is through defective cell cycle regulation. Re-
expression of SMARCB1 in human rhabdoid tumor cell lines
causes G0/G1 arrest showing that restoration of SMARCB1
expression is sufficient to suppress proliferation [14,15]. This is
associated with activation of p16INK4a and CDKN1A and down
regulation of E2F target genes including cyclin A, E2F1 and CDC6.
SMARCB1 arrest is critically dependent on the presence of
functional pRB [16]. SMARCB1 is not able to arrest cells lacking
functional pRB and arrest can also be reversed by disruption of
pRB repressor complexes through restoration of cyclin D1 and
cyclin E expression. Further, constituitively active pRB1 can
induce arrest in RT cell lines lacking SMARCB1.
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4482SMARCB1 is part of an ATP dependent multiprotein SWI/
SNF chromatin remodelling complex [17]. It associates with
ATPase subunits Brg1 (for Brahma-related gene 1, or SNF2b and
Brm (for Brahma or SNF2a). In contrast to SMARCB1, Brg1 and
Brm are required for cell cycle arrest mediated by pRB. Versteege
et al [16] hypothesize that Brg1 and Brm are necessary for the
chromatin remodelling associated with pRB repression of E2F and
that SMARCB1 has a promoting but not a primary role in this
remodelling. Deletion of Brg1 and Brm occurs in many cancer cell
lines and is associated with gene specific changes in promoter
methylation at CD44 and E-Cadherin leading to hyper-methylation
and gene silencing [18]. Brg1 and Brm associate directly with the
promoters of these genes and a more widespread role in epigenetic
regulation of gene expression during tumor progression has been
proposed. The direct role of SMARCB1 in chromatin remodelling
has not been extensively explored. Pan et al [19] have shown that
SMARCB1 represses the c-Fos promoter via histone deacetylation
in 293T cells and that this occurs via direct interactions between
HDAC4 and SMARCB1, and Zhang et al [20] showed that
interactions between HDAC1 and hSNF5/INI1 (SMARCB1)
were required to repress Cyclin D.
We hypothesized that the oncogenic pathway induced by
SMARCB1 inactivation in RT may involve epigenetic silencing of
key cell cycle target genes. This premise, if established, may reveal
opportunities for treatment of RT with epigenetic therapies that
restore the expression of key growth-regulating genes. In this work
we demonstrate that the imprinted cell cycle inhibitor CDKN1C
(OMIM 600856) is a downstream target for SMARCB1 epigenetic
regulation. SMARCB1 consistently activated CDKN1C expres-
sion via histone H3 and H4 acetylation at the CDKN1C promoter
and the histone deacetylase inhibitor (HDACi), romidepsin,
restored imprinted CDKN1C expression in RT cells through
promoter histone H3 and H4 acetylation. Significantly, CDKN1C
expression was absent or negligible in clinical specimens, enforced
expression of CDKN1C in G401 RT cells induced cell cycle arrest
and knockdown of endogenous CDKN1C increased proliferation
in G401 RT cells as well as attenuating the effects of SMARCB1
re-expression on cell proliferation. Our findings show that
CDKN1C silencing is common in RT, suggest that CDKN1C is
an important regulator of RT cell growth, and that RT cell
proliferation is mediated in part via suppression of CDKN1C
expression attributable to deletion of SMARCB1.
Results
CDKN1C is up-regulated in RT cells with reconstituted
expression of SMARCB1
CDKN1C (p57
Kip2) is commonly epigenetically silenced in
cancer and is the only imprinted member of the CIP KIP family of
cell cycle inhibitors. We hypothesized therefore that CDKN1C
(p57
Kip2) may be a potential downstream target for SMARCB1.
To examine this we expressed SMARCB1 under the control of an
inducible promoter in two renal RT cell lines, G401 and STM91-
01. G401 is an established renal RT cell line homozygously
deleted for SMARCB1 [1]. STM91-01 is derived from a lung
metastasis with 22q loss of heterozygosity and deletion of
SMARCB1 exons 1 to 5 on the retained allele. Deletion of
SMARCB1 protein in all RT cell lines used in the study was
confirmed by Western blotting and further evidence for SMARCB1
deletion or rearrangement was obtained by southern blotting
(results not shown).
G401 clones expressing SMARCB1 under the control of a
tamoxifen inducible promoter system (pcDNA3 UAS SMARCB1
and pEF puro/GEV) were selected in geneticin and puromycin.
Two G401 clones, F13 and F22, showing inducible SMARCB1
expression, were selected for further investigation. A pool of
STM91-01 cells (STMpc), transduced with a lentiviral vector
system (pF 56UAS Sv40 puro/ini1 and pF GEV16) was also
examined. SMARCB1 protein was readily detectable 24 hours
after exposure to 1 uM 4HT in all cultures, (Figure 1A). Cell cycle
analysis was performed on cultures of F22 cells 72 hours after
induction of SMARCB1 protein expression. In SMARCB1
expressing cells 41.4+/25% of cells were arrested in G0 compared
with 7.0+/21.4% in un-induced cells (Supplementary Figure
S1A), consistent with observations made previously that
SMARCB1 can induce cell cycle arrest [14–16]. In contrast,
STMpc cells induced to express SMARCB1 showed little change
in the cell cycle (Supplementary Figure S1A). One explanation for
this is that the parental line, STM91-01, is derived from a RT lung
metastasis and may have acquired additional oncogenic mutations
and hence greater resistance to growth inhibitory signals. Reincke
et al [21] also found this cell line difficult to transduce with
recombinant adenovirus containing SMARCB1 and reportedly
found inconsistent cell cycle changes following infection.
CDKN1C mRNA was elevated in all lines (F22, F13, STMpc)
following induction of SMARCB1 expression with 1 uM 4HT
whereas other CDK family members including CDKN1A (p21/
WAF1) and CDKN1B (p27) did not show uniform responses
following 4HT treatment (Figure 1B). Quantitative analysis of
CDKN1C expression by real-time PCR in F22 cells showed four-
fold increases in CDKN1C expression 24 hours following
SMARCB1 induction, and STMpc showed six-fold increases in
CDKN1C expression (Figure 1C). 1 uM 4HT alone had a
negligible effect on CDKN1C expression in parental G401 and
STM91-01 cultures demonstrating that the observed effect on
CDKN1C expression was directly attributable to the induction of
SMARCB1 protein (results not shown). Endogenous levels of
CDKN1C protein were low in un-induced F22 cells however
following SMARCB1 induction, were increased to levels consistent
with the proportional increase in CDKN1C transcript levels
(Figure 1D).
Enforced expression of CDKN1C arrests proliferation in
G401 cells and CDKN1C knock-down increases
proliferation and attenuates SMARCB1-induced
proliferation arrest
To examine the direct effect of induced CDKN1C expression in
rhabdoid tumor cells, G401 clones over-expressing full-length
human CDKN1C under the control of the tamoxifen inducible
promoter (pcDNA3 UAS CDKN1C and pEFpuro/GEV), were
selected in geneticin and puromycin. Induction of CDKN1C
protein in G401 cells induced cell cycle arrest (Figure 2A and
Supplementary Figure S1B). Endogenous CDKN1C protein was
not detectable by Western blotting at the short exposure time-
setting used to detect over-expression of CDKN1C. In clone G401
C1, expressing the highest level of CDKN1C protein, 24.7+/
21.67% of cells were arrested in G0, compared with 2.3+/
20.14% in un-induced cultures (Supplementary Figure S1B). To
further ascertain the functional significance of CDKN1C induc-
tion in RT cells, a CDKN1C siRNA pool was used to knock-down
the low level of endogenous CDKN1C in F22 cells, and to knock-
down CDKN1C mRNA induced following SMARCB1 re-
expression. CDKN1C siRNA transfection in F22 cells eliminated
CDKN1C expression and led to increased proliferation, as
measured by a greater positive change in MTS absorbance over
the first 48 hours following transfection, as compared with F22
cells treated with a non-targeting control siRNA (Figure 2B).
CDKN1C in Rhabdoid Tumor
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induction on restricting cell proliferation. Cells in which
SMARCB1 expression was induced with 1 uM 4HT by 24 hours
and transfected with CDKN1C siRNA, exhibited a significant and
reproducible positive increase in MTS absorbance between 24 and
48 hours, reflecting an increase in the number of proliferating cells
in the culture when compared with cells transfected with non-
targeting siRNA +4HT. This correlated with reduced levels of
CDKN1C mRNA after 48 hours in the +4HT CDKN1C siRNA-
treated cultures. Between 48 and 72 hours, cells in the 4HT and
non-targeting siRNA, CDKN1C siRNA, and CDKN1C siRNA
and 4HT cultures, showed a reduction in the number of viable
cells present. In the CDKN1C siRNA culture this likely reflects a
reduction in the rate of cell proliferation as the cells approach
senescence. In the cultures treated with non-targeting siRNA and
Figure 1. SMARCB1 induces CDKN1C expression in rhabdoid
tumor cell lines. (A). Western blot showing induction of SMARCB1
protein in G401 clones F13 and F22, and in a transduced pool of STM91-
01 cells, STMpc. Lanes show protein in un-induced (2) cells and in cells
induced with 4HT (+). (B) Gene expression examined by RT-PCR for
CDKN1C, CDKN1B, CDKN1A and the HPRT control gene in un-induced
(2) and in 4HT-induced (+) cells. The -ve lane represents the PCR
negative control, the RNA –ve control lane represents the negative
control for reverse transcription and the RT-ve control represents a
control for genomic contamination derived from the induced F22
sample. CDKN1C was amplified for 40 cycles and CDKN1B and CDKN1A
for 28 cycles. All primers were located in separate exons. (C) CDKN1C
expression normalized to the GUSB control gene, derived by real-time
quantitative pcr in un-induced (24HT) and in induced (+4HT) cultures
of F22 cells (upper panel) and in cultures of STMpc cells (lower panel).
The data represent the mean of three independent experiments and
the error bars represent the standard error of the mean. (D) Western
blot showing expression of endogenous CDKN1C protein pre and post
SMARCB1 induction with 4HT. Immunoblotting was performed with the
p57 Kip2 antibody from Cell Signaling Technologies with an exposure
time of 2 minutes.
doi:10.1371/journal.pone.0004482.g001
Figure 2. CDKN1C levels modulate growth in rhabdoid tumor
cells. (A) Western blot showing induction of CDKN1C protein in G401
clones C1 and C2. Western blotting was performed with the p57 (C20)
antibody (Santa Cruz Biotech) with an exposure time of 30 seconds. (B)
MTS proliferation assay and CDKN1C RT-PCR following siRNA treatment
in F22 cells. The bar graph represents the absorbance difference at each
time interval. The data shown is the mean of five independent
experiments and the error bars represent the standard error of the
mean. CDKN1C siRNA leads to increased proliferation in F22 cells and
attenuated proliferation arrest in the 24 to 48 hour time interval in F22
cells induced to express SMARCB1. These effects were positively
correlated with the levels of CDKN1C expression following CDKN1C
siRNA transfection determined after 35 PCR cycles (lower panel).
doi:10.1371/journal.pone.0004482.g002
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probably reflects the long-term effect of sustained SMARCB1
expression on cell viability. This may suggest that SMARCB1
modifies the expression of other genes in addition to CDKN1C
that affect cell proliferation and viability. Nevertheless these results
clearly show that CDKN1C is an important modulator of G401
growth as small changes in CDKN1C expression affect prolifer-
ation, and furthermore provide evidence for parallels between the
actions of SMARCB1 and CDKN1C in regulating RT prolifer-
ation.
SMARCB1 expression causes increased histone
acetylation at the CDKN1C promoter
To investigate the mechanism associated with the SMARCB1-
induced upregulation of CDKN1C in RT cells, a region within the
59CpG island spanning the CDKN1C transcription start site, from
241 to +114 was analysed for changes in methylation, pre and
post SMARCB1 induction. Methylation of this region has
previously been shown to correlate with silencing CDKN1C
expression in cancer cell lines [22]. Bisulphite sequencing on 10
clones pre and post induction with 4HT revealed that the
CDKN1C promoter was largely unmethylated in un-induced F22
and STMpc cells and remained unmethylated following
SMARCB1 induction, (Supplementary Figure S2). Furthermore,
treatment of parental G401 and STM91-01 cells with 2 uM
5aza2dC had no significant effect on CDKN1C expression
consistent with a lack of promoter methylation.
We then performed CDKN1C promoter chromatin immuno-
precipitation (ChIP) with antibodies to acetylated histones H3 and
H4, 48 hours post SMARCB1 induction. Quantitative PCR was
performed on recovered DNA spanning the CDKN1C transcription
start site from 272 to +89 and normalized to GAPDH [22]. Three
independent ChIP analyses each, on both F22 and STMpc
rhabdoid tumor cell lines, showed that the CDKN1C promoter is
acetylated in un-induced F22 and STMpc cells, however histone
H3 acetylation increased 2 fold in both cell lines following
SMARCB1 induction with 4HT. A less marked increase in histone
H4 acetylation was observed in both cell lines cells (Figure 3A and
B). Histone acetylation was also examined at the CDKN1A and
CDKN1B promoters in F22 cells. In contrast to acetylation of the
CDKN1C promoter, histone H3 acetylation was either unchanged
(CDKN1A promoter) or slightly decreased (CDKN1B promoter)
following SMARCB1 induction, and histone H4 acetylation was
not significantly changed at either promoter (Figure 3C and D).
These results show that SMARCB1 specifically acetylates histones
H3 and H4 at the CDKN1C promoter either directly, or indirectly
through the recruitment of histone acetyltransferases (HATs) or
through inhibition of histone deacetylases (HDACs).
CDKN1C is upregulated in RT cells by HDACi and
promoter histone acetylation is increased
Romidepsin is a potent broad-spectrum inhibitor of class 1 and
class II histone decetylases (reviewed in [23]). We reasoned that
HDACi might mimic the effect of SMARCB1 on CDKN1C.
CDKN1C expression was significantly increased in all RT cell
lines including G401, STM91-01, SJSC and BT16 lines following
treatment with 10 nM Romidepsin for 24 hours (Figure 4A to D).
Levels of CDKN1C mRNA induction quantified by real-time
PCR varied from six-fold in BT16 cells to twelve-fold in STM91-
01 cells. After 48 hours culture with 10 nM Romidepsin, cells
showed signs of apoptosis. This coincided with a decrease in the
levels of the GUSB house-keeping gene therefore the levels of
CDKN1C induction at 24 hours most reliably reflect the true
effect of Romidepsin on CDKN1C expression. The levels of
CDKN1C induction at 24 hours in G401 and STM91-01 cells
treated with Romidepsin slightly exceeded those induced with
SMARCB1. Cell cycle analysis was performed on G401 and
STM91-01 cells treated with 1 nM Romidepsin after 72 hours. In
both cell lines, this treatment led to a significant increase in the
percentage of cells in G0 (Supplementary Table S1). This was
more pronounced in G401 cells compared with STM91-01 cells.
In control G401 cells treated with 0.01% DMSO, 4.1+/20.35%
of cells were in G0 compared with 19.3+/21.6% in cultures
Figure 3. SMARCB1 increases histone acetylation at the
CDKN1C promoter. (A) Acetylation of histone H3 and histone H4 at
the CDKN1C promoter in un-induced (24HT) and in induced (+4HT) F22
cells. (B) Acetylation of histone H3 and histone H4 at the CDKN1C
promoter in un-induced (24HT) and in induced (+4HT) STMpc cells.
CDKN1C signal was normalized to GAPDH. Acetylation at histone H3
and H4 was increased at the CDKN1C promoter in both F22 and STMpc
cells. (C) Acetylation of histone H3 and histone H4 at the CDKN1A
promoter. (D) Acetylation of histone H3 and histone H4 at the CDKN1B
promoter. CDKN1A and CDKN1B signal was normalized to GAPDH. Error
bars represent the standard error of the mean and were derived from
three independent experiments.
doi:10.1371/journal.pone.0004482.g003
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cells treated with 0.01% DMSO were in G0 compared with
16.7+/22.0% treated with 1 nM Romidepsin. CDKN1C promoter
ChIP analysis was performed in G401 and STM91-01 post
treatment with 10 nM Romidepsin for 48 hours. Both histone H3
and H4 acetylation was significantly increased at the CDKN1C
promoter in treated cells, consistent with the increase in CDKN1C
expression, (Figure 5A). Increases in promoter histone acetylation
were also observed for CDKN1A however, these were not as
pronounced as the histone acetylation observed for CDKN1C
(Figure 5B). In contrast, CDKN1B did not show significant
increases in promoter histone acetylation following Romidepsin
treatment (Figure 5C).
CDKN1C allelic expression is modulated in RT cells with
reconstituted expression of SMARCB1 and with HDACi
To examine CDKN1C imprinting, we took advantage of deletion
polymorphisms within CDKN1C exon 1 in G401 and in STM91-
01 cells, [24,25]. CDKN1C alleles differing in size by 24 bp and
12 bp were identified in G401 and STM91-01 cells respectively
(Supplementary Figure S3). Both cell lines exhibited biallelic
expression, suggesting loss of imprinting. This is in contrast to
CDKN1C imprinting in the normal kidney where the gene shows
monoallelic expression [26]. The effect of SMARCB1 expression
on CDKN1C imprinting in G401 clones F13 and F22 and in the
STM91-01 pooled cells, STMpc, was examined. Induction of
SMARCB1 protein in F22 cells led to the restoration of
monoallelic CDKN1C expression with expression predominantly
from the short allele 24 hours post induction, and a trend towards
expression from the short CDKN1C allele in the weaker
SMARCB1 expressor, F13 (Figure 6A). 4HT alone had no
sustained effect on the pattern of allelic expression in parental
G401 cells, demonstrating specificity for the SMARCB1 effect. A
variable dominant expression from the long allele was sometimes
observed in different wild-type and recombinant un-induced G401
cells reflecting the unstable nature of CDKN1C imprinting in these
cultures. The short allele was however always reproducibly
expressed in replicate cultures following SMARCB1 induction in
the G401 background suggesting that SMARCB1 expression leads
to stabilization of the CDKN1C imprint and promotes monoallelic
expression. In contrast, induction of SMARCB1 expression in
STMpc cells did not alter biallelic expression of CDKN1C
(Figure 6A). We then examined allelic expression in response to
treatment with 0.3 uM TSA and 10 nM Romidepsin and
observed a shift to the short allele mimicking the effect of
SMARCB1 induction. This was most marked with 10 nM
Romidepsin (Figure 6B). The parental G401 line was also sensitive
to TSA and Romidepsin, and the direction of monoallelic
expression following treatment was identical to that observed in
F22 and F13 cells (Figure 6B). Consistent with the response to
SMARCB1 induction, TSA and Romidepsin had no effect on the
pattern of allelic expression in STM91-01 cells (Figure 6B). Taken
together these results show that SMARCB1 over-expression, and
HDACi drugs, have identical affects on the allelic expression of
CDKN1C.
Imprinting at CDKN1C is typically, although not exclusively,
regulated via maintenance of allele specific patterns of methylation
at the adjacent 11p15.5 Imprinting Centre 2 (IC2) involving
antisense transcription of the non-coding RNA, LIT1 [27,28].
Mosaic loss of methylation at IC2 may lead to low levels of biallelic
CDKN1C expression. However, in both G401 and STM91-01
cells, normal methylation at IC2 was observed suggesting that an
alternative mechanism is associated with loss of CDKN1C
imprinting in RT cell lines ( Supplementary Figure S4). Other
RT cell lines including SJSC and BT16 (not informative for
CDKN1C imprint analysis) also maintained normal methylation at
IC2 (results not shown).
CDKN1C expression is absent in rhabdoid tumor
specimens
TherelevanceofimpairedCDKN1CexpressioninRTcelllinesto
the aetiology of RT was further ascertained by examination of clinical
Figure 4. Romidepsin increases CDKN1C expression in rhabdoid tumor. CDKN1C expression normalized to the GUSB control gene in (A)
G401 (B) STM91-01 (C) SJSC and in (D) BT16 cells treated with 10 nM Romidepsin. All data represent the mean of three independent experiments and
the error bars represent the standard error of the mean.
doi:10.1371/journal.pone.0004482.g004
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on the basis of identified SMARCB1 mutations, absence of
SMARCB1proteinexpressionorhistologicalcriteria,wereexamined
for CDKN1C mRNA expression by RT-PCR and for CDKN1C
protein by immunohistochemistry. 6/6 tumors with viable mRNA
showed negligible or absent CDKN1C expression after 45 cycles of
RT-PCR, although CDKN1A and CDKN1B expression persisted in
these tumors, (Supplementary Figure S5A). All tumors examined by
immunohistochemistry (n=12) lacked nuclear staining for CDKN1C
and showed negligible cytoplasmic staining (Table 1 and Supple-
mentary Figure 5B). A subset of RT show loss of CDKN1C protein
even in the presence of detectable wild-type SMARCB1 suggesting
that additional genetic factors may contribute to CDKN1C silencing in
rhabdoid and related tumors. Four tumor specimens, with confirmed
SMARCB1 mutations, and lacking CDKN1C expression, exhibited
methylation indices at IC2 within the normal range (results not
shown) suggesting that epigenetic change at IC2 is not responsible for
CDKN1C silencing in primary rhabdoid tumors, consistent with
observations in RT cell lines. There was insufficient DNA available
from SMARCB1 expressing tumors for IC2 methylation analysis by
Figure 5. Romidepsin increases histone acetylation at the CDKN1C promoter. (A) Acetylation of histone H3 and histone H4 at the CDKN1C
promoter in G401 and in STM91-01 cells treated with 10 nM Romidepsin and in control cells treated with 0.01%DMSO. Acetylation at both histone H3
and histone H4 was significantly increased in both treated cultures. (B) Acetylation of histone H3 and histone H4 at the CDKN1A promoter in G401
and in STM91-01 cells treated with 10 nM Romidepsin and in control cells treated with 0.01%DMSO. Histone acetylation is increased in both cell lines
following Romidepsin treatment although the increases are not as marked as those seen at the CDKN1C promoter following Romidepsin treatment.
(C). Acetylation of histone H3 and histone H4 at the CDKN1B promoter in G401 and in STM91-01 cells treated with 10 nM Romidepsin and in control
cells treated with 0.01%DMSO.
doi:10.1371/journal.pone.0004482.g005
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contribute to the absence of CDKN1C expression within this sub-set.
Discussion
In this study we identify the imprinted cell cycle regulator,
CDKN1C, as a new and important SMARCB1 target in RT and
furthermore demonstrate that SMARCB1 has the capacity to
restore the expression of genes that are epigenetically silenced,
consistent with its proposed role in chromatin remodelling. We
show evidence that the mechanism by which CDKN1C expression
is induced by SMARCB1 is via increased promoter histone H3
and H4 acetylation and that the HDACi, Romidepsin, activates
CDKN1C expression in a related manner, leading to cell cycle
arrest in RT cell lines. The parallel effects of SMARCB1 and
HDACi, in association with an absence of CDKN1C expression in
clinical specimens of rhabdoid tumor, and the demonstrated
sensitivity of RT cell lines to small changes in CDKN1C
expression mediated via siRNA, suggest that loss of CDKN1C is
integral to the aetiology of RT, and furthermore that RT may be
responsive to specific HDACi that increase endogenous levels of
CDKN1C. This study reveals new insight into the molecular
aetiology of malignant RT.
Cell cycle regulators have been previously studied in RT cell
lines. SMARCB1 is a transcriptional co-activator of p16
INK4a and is
required to bring the BRG1 chromatin remodelling complex to
the p16
INK4a promoter. Activation of p16
INK4a inhibits the Cyclin
D-CDK4 complex with the result that pRB is retained in its anti-
proliferative hypo-phosphorylated state and cells arrest in G1
[15,16,29]. pRB is the critical endpoint for G1 arrest in RT. The
CIP KIP family member CDKN1A is a critical effector of signal
transduction pathways and has also previously been implicated as
a downstream target for SMARCB1 in RT cell lines [14]. CIP
KIP inhibitors bind and inhibit the kinase activity of CDK-cyclin
complexes including Cyclin A-CDK2 and Cyclin E-CDK2
through a common shared N-terminal domain. CDKN1A is up-
regulated following re-expression of SMARCB1, and expression is
coincident with G1 arrest in these cells [14]. Cyclin E can
overcome SMARCB1 induced proliferation arrest in RT cell lines
also implying involvement of CIP KIP inhibitors in rhabdoid
tumor, however in other studies CDKN1A and CDKN1B
expression were unchanged by SMARCB1 expression [16]. We
identified minor transcriptional upregulation of CDKN1A or
CDKN1B in two different RT cell backgrounds following
transfection with SMARCB1 however, expression of these genes
persisted in clinical specimens of ATRT with inactivated
SMARCB1 arguing against a major role in rhabdoid tumor
aetiology.
CDKN1C is a third member of the CIP KIP family. CDKN1C is
regulated by p73 during mitotic exit and re-entry into G1 in T98G
glioma cells and in myogenic differentiation, CDKN1C expression
is induced by p73 and p63 to maintain pRB in an active
hypophophorylated state [30]. CDKN1C is not transactivated by
p53 [31]. Our results therefore suggest that SMARCB1 could be
part of a pathway involving p73 or alternatively that SMARCB1
independently regulates CDKN1C. Due to a lack of suitable
SMARCB1 antibodies for immunoprecipitation, we were unable
to perform ChIP experiments to show whether SMARCB1
transactivated CDKN1C by direct promoter binding.
CDKN1C is expressed in human fetal brain and has been
implicated in regulating the migration of neurons entering the
neural plate and in the later stages of neurogenesis in driving the
differentiation of oligodendrocyte precursor cells [32,33].
CDKN1C is also not expressed in human astrocytomas however
re-expression leads to a G1 block associated with hypopho-
sphorylation of pRB, consistent with a tumor suppressor role [34].
Significantly and perhaps not surprisingly we found that
CDKN1C expression was absent from the clinical tumor
specimens we examined, of which the majority were CNS AT/
RT, and our evidence from RT cell lines also supports an
important role for CDKN1C in RT growth suppression.
Silencing of CDKN1C in cancer is usually epigenetic and
associated with promoter methylation or histone deacetylation
[22]. In gastric tumors both mechanisms silence CDKN1C and
expression can be restored by demethylating reagents in cases
where the promoter is hypermethylated or by HDACi in cases
where promoter histones are deacetylated [35]. Growth suppres-
sion in CDKN1C-transduced leukaemia cell lines is dependent on
the extent of endogenous CDKN1C promoter methylation within
Figure 6. SMARCB1 and HDACi have identical effects on allelic
expression of CDKN1C. (A) CDKN1C allelic expression in un-induced
and in induced cultures of G401, F22, F13, STM91-01 and in STMpc cells.
Changes in the pattern of allelic expression can be seen in F22 and in
F13 cells following induction of SMARCB1 expression with 1 uM 4HT.
Wild-type G401 cells did not show any change in allelic expression
following 4HT treatment. Biallelic CDKN1C expression persisted in
STM91-01 cells and in STMpc cells. (B) CDKN1C allelic expression in un-
induced cultures of F22 and F13 with 0.01% DMSO and 10 nM
Romidepsin and in G401 cells. Changes in allelic expression can be seen
with Romidepsin treatment in F13, F22 cells and in wild-type G401 cells.
As with SMARCB1 induction in STMpc cells, allelic expression in STM91-
01 cells was unchanged following Romidpesin treatment.
doi:10.1371/journal.pone.0004482.g006
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methylation of the cell cycle control pathway including p73, p15
and CDKN1C defines a subset of ALL patients with poor prognosis
[37]. Evidence also exists for CDKN1C silencing in lung and breast
cancer by promoter methylation [38]. Our results, showing
increases in histone acetylation at the CDKN1C promoter in RT
cell lines, following treatment of the cells with Romidepsin and
following SMARCB1 induction, suggest that CDKN1C is epige-
netically silenced in RT by histone deacetylation at the promoter,
and that SMARCB1 is complexed with histone acetyl transferases
or that it may have instrinsic acetylation properties. The
promoters of CDKN1A and CDKN1B were not significantly affected
by SMARCB1 induction and these genes exhibited minor changes
in expression. In contrast, CDKN1C expression was markedly
increased and this coincided with a specific increase in histone H3
acetylation and less marked increase in histone H4 acetylation.
The predominant acetylation at histone H3 is consistent with
studies showing that the transcriptionally active murine cdkn1c
promoter is associated with acetylated histone H3 [39].
CDKN1C is a paternally imprinted gene and in most normal
tissues is expressed from the maternal allele although frequently
leaky expression also occurs from the paternal allele. SMARCB1
over-expression and HDACi did not universally induce mono-
allelic transcription of CDKN1C in all cell lines suggesting that
SMARCB1 cannot be involved in establishing imprinting at
CDKN1C, but that it is able to recognize and induce transcription
from appropriately imprinted alleles. Significantly LIT1 methyl-
ation was normal in RT cell lines and in RT with loss of
SMARCB1 function, demonstrating that loss of CDKN1C
imprinting must involve mechanisms independent of IC2 on
11p15.5.
Cdkn1c has been recently shown to be a critical regulator of
embryonic growth and is the only CIP KIP protein that is
imprinted and essential for normal development [40]. 50% of
patients with the overgrowth disorder Beckwith Wiedemann
syndrome commonly have epigenetic silencing of CDKN1C caused
by a methylation defect within IC2 on 11p15.5. These patients are
at risk for cancer in early childhood. The spectrum of tumors in
IC2 imprinting defect cases includes hepatoblastoma, rhabdomyo-
sarcoma and gonadoblastoma [41] although these affect fewer
than 5% of these patients. Jackson et al [42] recently reported a
case with BWS and an IC2 defect with ATRT. However the
ATRT also bore somatic loss of 22q and an inactivating
SMARCB1 mutation, demonstrating that germ-line inactivation
of CDKN1C was not sufficient to cause ATRT. This is consistent
with the widespread inactivation of CDKN1C in many different
cancers with additional oncogenic mutations and suggests that
CDKN1C silencing contributes, but is alone insufficient, to cause
tumors. Germline SMARCB1 mutations have been recently
described in rare families with predisposition to RT and to
schwannomatosis [5,12,13]. It might be expected that individuals
carrying inactivating mutations in SMARCB1 in the germline
might display phenotypic features in line with impaired CDKN1C
expression such as high birth weight. However this has not been
reported in the literature and too few cases have been identified to
date to directly examine these associations.
The fact that epigenetic silencing of CDKN1C is so widespread
in human cancer makes it an attractive target for epigenetic
therapies. To our knowledge it has not been previously identified
as a target for Romidepsin. The promoter of CDKN1A is however
frequently acetylated by HDACi and expression is induced
(reviewed in [43]). The fact that CDKN1C is an imprinted gene
makes it a more attractive target as its imprinted status provides an
additional layer of developmental regulation and implies that
comparatively small changes in expression in embryonic-like cells
are likely to have potent effects on cell proliferation and
differentiation [40]. In addition it has recently been shown to be
a critical regulator of embryonic growth regulating through IGF1,
a growth factor frequently abnormally expressed in human cancer.
In summary we have demonstrated that CDKN1C is an
important target for SMARCB1 and that RT cells are sensitive
to small changes in CDKN1C expression. We show for the first
time that SMARCB1 has a role in CDKN1C promoter histone
acetylation suggesting opportunities for further investigation of
signalling pathways that may be epigenetically regulated by
SMARCB1. Furthermore as Romidepsin restores CDKN1C pro-
Table 1. Molecular genetic features of ATRT.
Tumor Mutation Prediction
SMARCB1
protein Tumor site 22qLOH
CDKN1C
mRNA
CDKN1C
protein
1502 None Yes CNS No NA No
1552 None Yes CNS No NA No
1595 None Yes Renal No NA No
1758 None Yes Posterior fossa Yes NA No
1877 c118C.T (exon 2) ARG40STOP No abdominal Yes No No
1918 None No Chloroid plexus Yes NA No
1938 c1144delG (exon 9) Frame shift No CNS Yes faint No
1993 c325insG (exon 3) Frame shift No CNS Yes faint No
3022 None Yes Renal Yes No No
3074 Homozygous deletion of gene No protein made No CNS Yes No No
3161 c601C.T (exon 5) ARG201STOP No CNS No faint No
c795+2 indel ATGA Splice donor mut
n removes exon 6
3180 c157C.T (exon 2) ARG53STOP No CNS No NA No
c569–570 ins18 (exon 5) Frame shift
Table 1 summarizes the molecular genetics of clinical specimens of ATRT. In tumor 3074 SMARCB1 was homozygously deleted. In tumors 3161 and 3180 two
independent SMARCB1 mutations were identified. NA; tumor RNA was not available.
doi:10.1371/journal.pone.0004482.t001
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expression, we propose that Romidepsin and related compounds
could be further explored as therapeutic reagents in the treatment
of RT through restoration of gene expression patterns lost as a
result of SMARCB1 inactivation.
Materials and Methods
Cell lines and cell culture
The G401 RT cell line was obtained from the American Type
Culture Collection (ATCC). The establishment of STM91-01,
BT16 and SJSC were previously reported [44,45]. These RT cell
lines were maintained in RPMI 1640 supplemented with 10% fetal
calf serum (FCS) and grown at 37uC in 5%CO2. SMARCB1
recombinant STM91-01 cells were grown in the same media
supplemented with 100 mg/mL hygromycin (Roche, Mannheim,
Germany) and 1 mg/mL puromycin (Sigma Chemical Company,
St. Louis, MO). G401 cells were maintained in McCoy’s 5A
modified media supplemented with 10% FCS, and both SMARCB1
and CDKN1C recombinant G401 clones were grown in the same
media supplemented with 600 mg/mL geneticin (Invitrogen,
Groningen, Netherlands) and 5 mg/mL puromycin (Sigma).
Induction of SMARCB1 and CDKN1C in transformed cell
lines was achieved by the addition of 1 mM 4-hydroxytamoxifen
(4HT: Sigma Aldrich Castle Hill Australia). 4HT (1 mM) and
Trichostatin A (TSA; Sigma Aldrich) (3.0 mM) were prepared in
100% ethanol. Romidepsin (10 mM)(Gloucester Pharmaceuticals)
and 5-Aza-29-deoxycytidine (5aza2dC; Sigma Aldrich) (2 mM)
were prepared in 100% DMSO and stored in aliquots at 220uC.
Appropriate dilutions were made into culture medium for
experimental analyses. Relevant solvent controls were included
in all experiments. Culture media and reagents were replaced
every 24 hrs.
For imprinting and gene expression assays, cells were plated as
replicate cultures at 2610
5 cells/well in 2 ml culture volumes.
Cells were trypsinized at 24 hourly time points, over a total time-
course of 72 hours, washed in PBS, and pellets were frozen at
280uC for future RNA and DNA extraction.
Southern blotting
To confirm SMARCB1 deletion or rearrangement in RT cell
lines and in clinical specimens of rhabdoid tumor, 10 ug of RT cell
line genomic DNA was digested with a panel of restriction
enzymes and run overnight on 0.8% agarose gels alongside normal
human genomic DNA as a control. DNA was transferred
overnight in 206 SSC buffer onto Zeta Probe
R GT Genomic
tested blotting membrane (Biorad, Hercules CA 94547). Mem-
branes were fixed under UV light, prehybridized at 60uCi n
ExpressHyb buffer (Clontech, Mountain View CA 94043) and
hybridized with a
32P-labelled full length SMARCB1 PCR product,
prepared by the random priming method, for 18 hours.
Membranes were washed at room temperature with 26 SSC /
0.05% SDS for 40 mins and then with 0.16SSC / 0.1% SDS for
a further 40 mins at 55uC and exposed to phosphoimager screens
for 24 to 48 hours. Bands were visualized with ImageQuant TL
v2003.02 software following digital capture on a scanning
phosphoimager (Molecular Dynamics).
Cell cycle analysis
5610
5 cells were seeded and treated for 72 hrs. Media was
replaced each 24 hrs. 5610
5 cells were stained for cell cycle
analysis using a modified flow cytometry assay [46]. Briefly, 5610
5
cells were collected, washed in PBS/0.1% FCS, fixed with 1%
formaldehyde (Polysciences, Warrington, PA) on ice for 30 mins,
then permeabilized on ice with 0.5% Triton X-100 in PBS (Roche)
for a further 15 mins. Cells were then incubated on ice in the dark
for 45 mins with either PE-conjugated mouse anti-human Ki67
monoclonal antibody or PE-conjugated mouse IgG1 k monoclo-
nal isotype control (BD Biosciences). After a final wash with PBS/
0.1% FCS, cells were resuspended in 0.3 mL of washing buffer
containing 1 mg/mL of 7-aminoactinomycin D (7AAD; Molecular
Probes, Eugene, USA). Flow cytometric analysis was performed on
a LSRII analyser (Becton Dickson) and data analysed using the
FACS Diva software program. For each sample, electronic gating
was performed on the intact, single cell population. Ki67
expression and 7AAD signal intensity were used to determine
the cell cycle status of viable cells.
Inducible expression system
ThehumanSMARCB1codingsequencewasPCRamplifiedfrom
plasmid (PCR4-TOPO-INI1) containing full-length human
SMARCB1,usingforwardprimer59-GGATCCACCATGATGAT-
GATGGCGCTGAGC-39 and reverse primer 59-GCCTCGAGT-
TACCAGGCCGGGGCCGTGTTGG-39containingBamH1and
Xho1 restriction sites respectively. The PCR product was digested
withBamH1andXho1and insertedintothevectorpcDNA3UAS/
neo (kindly provided by Dr.J.Silke, La Trobe University, Victoria,
Australia ). The integrity of the construct was verified by direct
automated sequencing. The vector was linearized and then co-
transfected with a second linearized vector, pEF puro/GEV, into
G401 cells. Transfection was achieved using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. Cells
containing both pcDNA3 UAS SMARCB1 and pEF puro/GEV
were doubly selected in geneticin and puromycin. Single cells were
selected and grown and clones were tested for SMARCB1 expression
by Western blotting following the addition of 1 uM 4HT. The full
length human CDKN1C coding sequence was PCR amplified from
plasmid (pCMV6-XL4 CDKN1C) (Origene Technologies, Rock-
ville, MD), using forward primer 59 GCGGTACCACCATGTCC-
GACGCGTCCCTCC-39 and reverse primer 59-GCGGATCCT-
CACCGCAGCCTCTTGCG-39 containing Kpn1 and BamH1
restriction sites respectively. The PCR product was digested with
Kpn1 and BamH1 and inserted into the vector pcDNA3 UAS/neo.
Transfection and selection in G401 cells was the same as for
SMARCB1 and clones were tested for CDKN1C expression by
western blotting following the addition of 1 uM 4HT.
Lentiviral production and transfection
The STM91-01 cell line was found to be refractory to
transfection using the above vector system and a lentiviral system
was used to produce pooled recombinant cell lines [47].
The human SMARCB1 coding sequence was amplified and cloned
into the BamHI and XbaI sites of the vector, pF 56UAS Sv40 puro,
using the same forward primer as above and a modified reverse
primer, 59-GCTCTAGATTACCAGGCCGGGGCCGTGTTGG-
39. HEK 293T cells were transiently transfected with pF 56UAS
Sv40 puro containing SMARCB1or pF GEV16 hygro vector with
the packaging vectors pCMVdR8.2 and VSVG, using Effectene
(Qiagen, Hilden Germany) as described by the manufacturer. The
media was changed after 16 hrs and virus-containing supernatant
was collected after 48 hours, filtered through 0.45 mmM i l l i p o r e
filters, and frozen at 280uC.
For transduction in STM91-01 cells, 1610
6 of the target cells
were washed in PBS and then incubated in virus-containing media
containing 5 mg/mL polybrene (Sigma Aldrich) in 6-well plates.
Plates were then spun at 2500 rpm for 90 mins at 30uC, incubated
for a further 90 mins at 30uC, then returned to 37uC in 5%CO2.
Media was changed the next day and 2 days after transduction the
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GEV16 hygro virus and selected in hygromycin. Hygromycin
resistant cells were then infected with pF 56UAS Sv40 puro/ini1
virus followed by selection in puromycin. A pool of resistant cells
was then tested for SMARCB1 expression by western blotting
following the addition of 1 uM 4HT.
siRNA transfection
Optimal transfection conditions for G401 F22 cells were
determined using BLOCK-iT fluorescent oligo (Invitrogen). Cells
were plated at optimal density for the culture plate used and
allowed to adhere overnight. ON-TARGETplus SMARTpool
CDKN1C siRNA (Dharmacon, CO, USA) was transfected at a
final concentration of 10 nM in the presence of 3 mg/mL
DharmaFECT2 transfection reagent (Dharmacon) according to
the manufacturer’s instructions. Additionally, ON-TARGETplus
siCONTROL Non-targeting pool (Dharmacon) was transfected in
the same manner as a control (mock) transfection. 6 hrs after
transfection, 1 mM 4HT or ethanol control was added to induce
SMARCB1 expression. Media was refreshed every 24 hrs,
maintaining 1 uM 4HT or ETOH, as required, with 1 nM oligo.
Cells were harvested at 24 hr intervals for RNA extraction and for
determination of cell proliferation by the MTS assay. CDKN1C
expression was examined as described under ‘‘Gene expression
and imprinting’’. Cell proliferation was measured by the MTS-
based CellTiter 96 Aqueous non-radioactive cell proliferation
assay (Promega, WI, USA). Briefly, triplicate wells of siRNA
transfected cells, induced or un-induced for SMARCB1, were
incubated with [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS)/
phenazine methosulfate (PMS) solution for 2 hrs at 37uC. Well
absorbance was measured at 492 nm and a reference wavelength
of 620 nm using a Multiskan ES spectrophotometer (Thermo
Electron, ON, Canada) at 24 hourly time intervals. The
absorbance at each time interval was normalized in each culture
to the t0 absorbance value, which was set to 1.0. Absorbance
differences in each 24 hour interval, reflecting the rate of
proliferation in individual cultures, were calculated by subtraction
of normalized absorbance values.
Western blotting
Cell pellets containing at least 2610
5 cells were lysed in
mammalian lysis buffer (50 mM Tris, pH 7.5; 375 mM NaCl;
1 mM ethylenediamine tetraacetic acid; 1% Triton X-100) and
then sonicated to shear DNA. Total protein was determined
using the Bicinchoninic (BCA) protein assay (Sigma Aldrich)
according to the manufacturer’s instructions. Twenty micrograms
of protein were separated on 12% sodium dodecyl sulfate-
polyacrylamide gels, transferred onto Hybond-P nitrocellulose
membrane (Amersham, Buckinghamshire, England), blocked with
5% non-fat dry milk in phosphate-buffered saline (PBS), and
probed with the indicated antibodies in 5% non-fat dry milk in
PBS with 0.05% Tween-20. HRP-conjugated antibodies were
detected using Super-SignalH West Dura Extended Duration
Substrate (Pierce, Rockford, IL) and exposing to film (Hyperfilm
MP, Amersham). The following antibodies were used for
immunoblotting: BAF47 (BD Pharmingen, San Diego, CA)
detecting SMARCB1, b-actin (Sigma Aldrich, p57 (C20) (Santa
Cruz Biotech, Santa Cruz, CA) or p57 Kip2 (Cell Signaling
Technology, Danvers MA USA) detecting CDKN1C, b-actin
(Sigma Aldrich), an anti-mouse immunoglobulin-G HRP (Sigma
Aldrich) and an anti-goat immunoglobulin-G HRP (Sigma
Aldrich) secondary antibody.
Gene expression and imprinting
Genomic DNA was extracted from RT cell pellets, comprising
at least 2610
5 cells, using the DNeasy Blood and Tissue kit
(Qiagen) according to the manufacturer’s instructions. CDKN1C
primers F4 (59 GCGTTCTACCGCGAGACG 39) and R5 (59
CGAGTGCAGCTGGTCAGCGAG 39) were used to amplify
across the region of deletion polymorphisms in exon 1 using the
Enhancer PCR system (Invitrogen Corporation CA 92006) and Hi
Fi Taq polymerase (Roche, Mannheim, Germany). PCR products
were digested with PvuII and separated on 6% non-denaturing
polyacryamide gels containing 10% glycerol to identify polymor-
phisms required for imprinting analysis as previously described
[26]. Bands were visualised by staining with ethidium bromide and
digital images were captured following UV exposure on a Biorad
Gel Doc 1000 system. PCR products were sequenced using Big
Dye terminator technology to determine allele sizes.
RNA was extracted from RT cell pellets comprising at least
2610
5 cells, using the RNeasy Mini kit (Qiagen) according to the
manufacturer’s instructions. 1 ug of RNA was reverse transcribed
with random primers (pd(N)6) (Amersham Pharmacia Biotech)
and M-MLV Reverse Transcriptase RNaseH minus (Promega
Corporation). CDKN1C was amplified with primers F2
(59GCAGCTGCCTAGTGTCCCGGTC 39) in exon 1 and R7
(59 TAAAT TGGCTCACCGCAGCC 39) spanning exons 2 and
3 within the 39UTR using the Enhancer PCR system with Hi Fi
Taq polymerase. Cycling was 95uC for 3 mins, 45 cycles of 95uC
for 45 secs, 56uC for 30 secs, 68uC for 1 min 30 secs and a final
extensions step at 68uC for 10 mins. PCR products were digested
with PvuII and electrophoresed as described above.
CDKN1A (p21) was amplified with primers p21F (59 GAGG-
CACCGAGGCACTCAGAG 39) and p21R (59 GGCACAAGGG-
TACAAGACAG 39) using Go Taq Green master mix (Promega
Corporation). Primers were located in exon 1 and 2 respectively to
ensure specificity for cDNA. CDKN1B (p27) was amplified with
primers p27F (59 CCATGTCAAACGTGCGAGTGT 39)a n d
p27R (59 CGTTTGACGTCTTCTGAGG 39) using Go Taq
Greenmastermix.CDKN1Bprimerswerelocatedinseparateexons.
PCR cycling for CDKN1A and CDKN1B was at 94uC for 5 minutes,
94uC 30 secs, 55uC for 30 secs, 72uC for 30 secs for at least 28
cycles, followed by a final step at 72uC for 5 minutes.
Real-time Q-PCR for CDKN1C expression was performed
using the primer and Taqman probe combination described in
Niemitz et al [48]. These were p57 1044F 59 GCGGCGATCAA-
GAAGCTG 39 and p57 1124R 59 CGACGACTTCT-
CAGGCGC 39 with probe p57 1069T FAM 59
CTCTGATCTCCGATTTCTTCGCCAAGC 39 TAMRA. Re-
actions were performed using a Quantitect Probe PCR probe
mastermix (Qiagen) and run in triplicate on a Rotorgene 3000
real-time thermal cycler (Corbett Technologies, Sydney Australia).
Reaction tubes were set up using the CAS1200 robotic system of
Corbett Technologies. Data was analysed using the Rotorgene’s
comparative quantitation software using selected untreated
samples as the calibrator. Expression of the housekeeping gene,
glucuronidase beta (GUSB), was examined by Q-PCR using the
Quantitect Probe PCR kit (Qiagen) according to the manufactur-
er’s instructions. Reactions were set up and performed in triplicate
as for CDKN1C. Data was analysed using comparative quanti-
tation software and untreated samples were used as the calibrator
as for CDKN1C. CDKN1C data was normalized to GUSB to
derive relative changes in CDKN1C expression. Levels of GUSB
remained stable in all reactions, however after 48 hours of
treatment with 10 nM Romidepsin, GUSB levels were noted to
decline in the RT cell lines.
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Immunoprecipitation
Methylation at LIT1 (OMIM 604115) was examined by
southern blotting following digestion of 5 ug of DNA with EcoRI
and NotI. Southern blots were probed with the probe DMRP
recognizing a 4.2 kb methylated and 2.7 kb unmethylated band
[27]. Prehybridization, hybridization and washing steps were as
described for southern blotting above. Bands were visualized and
quantified with ImageQuant TL v2003.02 software following
digital capture on a scanning phosphoimager (Molecular Dynam-
ics). The methylation index was calculated as the peak volume of
the methylated band divided by the sum of the volumes of the
methylated and unmethylated bands after background subtraction.
Methylation within the CDKN1C promoter was analysed by
sequencing bisulphite-modified DNA.1 ug of DNA extracted from
RT cells was bisulphite modified using the MethyEasy
TM DNA
Bisulphite Modification Kit (Human Genetic Signatures Pty Ltd
NSW Australia). Modified DNA easy was amplified using primers
p57-CF 59 GGTTGGGYGTTTTATAGGTTA 39 and p57-CR
59 ACCTAACTATCCGATAATAAACTCTTC 39 generating a
155 bp product derived from the region across the CDKN1C
transcription start site from 241 to +114 as described in Kikuchi
et al [22]. The amplified product was then cloned into the PCR-
Script Amp cloning vector (Stratagene, La Jolla CA). Cloning and
transformation were performed as recommended in the PCR-
Script
TM Amp Cloning kit (Stratagene). Selected blue colonies
were grown in liquid media and plasmid DNA was extracted and
purified using the QIAprep
R Spin Miniprep Kit (Qiagen). Plasmid
DNA was sequenced using Big Dye terminator technology
(Applied Biosystems) according to the manufacturer’s instructions
using vector primer T7. At least ten plasmids each were sequenced
from un-induced and 4HT-induced RT cultures.
Chromatin immunoprecipitation was performed exactly as
described in the protocols provided with the Acetyl-Histone H4
and H3 Immunoprecipitation (ChIP) assay kits (Upstate cell
signalling solutions Temecula CA 92590). Sonication was per-
formed by pulsing three times for 10 seconds at 30% power, using a
Vibra Cell
TM ultrasonic processor (SONICS). Sheared DNA was
examined on 1% agarose gels. DNA bound to immunoprecipitated
histone was recovered by phenol/chloroform extraction and
ethanol precipitation.PCR on ChIP’d DNA was performed across
the CDKN1C transcription start site from 272 to +89 as described in
Kikuchi et al [22]. Primers were p57 ChIP F 59 GTA-
TAAAGGGGGCGCAGGCGGGCT 39 and p57 ChIP R 59
TGGTGGACTCTTCTGCGTCGGGTTC 39 (product 161 bp).
2 uL of DNA was amplified in a reaction volume of 25 uL
containing 16Sybr Green, 16Sensimix, 0.25 mM MgCl2, and 10
picomoles of each primer as per the recommendations in the 26
Sensimix DNA kit (Quantace, London). Cycling was 95uC for
10 mins, 45 cycles of 95uC for 15 secs, 62uC for 15 secs, 72uC for
20 secs followed by a melt step ramping from 72 to 95uC. GAPDH
was amplified using primers GAPDH ChIPF 59
TCGGTGCGTGCCCAGTTGAACC 39 and GAPDH ChIPR
59 ATGCGGCTGACTGTCGAACAGGAG 39 (product 246 bp)
under the same conditions. Reactions were set up in triplicate for
each sample on a CAS1200 robotic system and run on a Rotorgene
3000 real-time thermal cycler (Corbett Technologies). Reaction
conditions were designed to eliminate primer dimer formation. The
comparative quantitation option in the Rotorgene software was
used to analyse the data. A normal control DNA sample run in
triplicate was used as the calibrator for both CDKN1C and
GAPDH. CDKN1C/GAPDH ratios were derived for each run.
CDKN1A and CDKN1B promoters in ChIP fractions were examined
in a similar manner using CDKN1A promoter primers described in
Takai et al [49] and CDKN1B promoter primers described in Li et al
[50]. These were p21F PROM 5 9GGTGTCTAGGTGCTC-
CAGGT 39 and p21R PROM 59 GCACTCTCCAGGAGGA-
CACA 39 (product 255 bp), p27F PROM 59 GTCCCTTC-
CAGCTGTCACAT 39 and p27R PROM 59 GGAAAC-
CAACCTTCCGTTCT 39 (product 162 bp). Sensimix reaction
mixes were as described for CDKN1C and GAPDH however
additional MgCl2 was not added. CDKN1A cycling was 95uC for
10 mins, 45 cycles of 95uC for 15 secs, 61uC for 15 secs, 72uC for
20 secs followed by a melt step ramping from 72uCt o9 5 uC.
CDKN1B cycling was 95uC for 10 mins, 45 cycles of 95uC for
15 secs, 57uC for 15 secs, 72uC for 20 secs followed by a melt step
ramping from 72uCt o9 5 uC. Reaction conditions were designed to
eliminate primer dimer formation.
Tissues and mutation screening in ATRT
Specimens with a clinical diagnosis of RT were submitted to the
laboratory for molecular diagnostic testing for SMARCB1 muta-
tion, or absence of SMARCB1 protein [51], after obtaining
informed consent. Analysis of clinical samples was approved by the
institutional ethics committee under approval number RCH
HREC 24073A. RNA was extracted from frozen sections using
the RNeasy mini kit (Qiagen) and DNA was extracted from either
frozen sections or formalin-fixed tissue using protocols described in
the DNeasy Blood and Tissue kit (Qiagen). cDNA was prepared in
a total volume of 40 uL from 1 ug RNA as described above for
RT cell lines. Allele loss studies were performed using microsat-
ellite markers mapping to 22q, on both blood and tumor DNA.
Markers analysed included D22S303, D22S257, D22S301,
D22S345, D22S1685 and TOPIP2. Alleles were examined by
PCR amplification of 50–100 ng DNA using primers end-labelled
with Fam, Hex or Tet. PCR products were electrophoresed on
4.5% 0.2 mm denaturing polyacrylamide gels on an ABI 377
DNA sequencer employing TAMRA 500 (Red) size standard.
Sample lanes were tracked with Genescan software Version 3.1.2
and analysed using Genotyper Version 2.1. Mutation screening
was performed by direct DNA sequencing of PCR products.
Primers were located in introns flanking individual exons and were
designed to amplify exonic and flanking splice site sequences. Exon
1 was divided into two separate overlapping fragments for PCR.
Primer sequences and reaction conditions are available on request.
Sequence analysis was performed by both manual inspection and
with Mutation Surveyor (Softgenetics PA 16803). BLAST analysis
was performed against genome databases.
Immunohistochemistry
Immunohistochemical stains were performed on representative
formalin-fixed paraffin-embedded tissue sections of a thickness of 2
micron using the monoclonal antibodies INI-1/BAF-47 (clone 25/
BAF47, 1:10, BD Biosciences, North Ryde, Australia) and p57/
KIP2 (clone 25B2, 1:200, Novocastra, Newcastle, UK) [51,52].
Heat-induced antigen retrieval was performed for 20 minutes at
100uC at pH 6.0 and 9.0, respectively, using target retrieval
solution (Dako, Copenhagen, Denmark). The detection system
used was standard streptavidin-biotin peroxidase complex
(DAKO, Copenhagen, Denmark) with diaminobenzidine as the
chromogen. The slides were counterstained with haematoxylin.
Supporting Information
Figure S1 Cell cycle effects of SMARCB1 and CDKN1C. A.
Cell cycle analysis in control cultures and in cultures induced to
express SMARCB1. The data represents the mean from three
independent experiments and the error bars represent the
CDKN1C in Rhabdoid Tumor
PLoS ONE | www.plosone.org 11 February 2009 | Volume 4 | Issue 2 | e4482standard error of the mean. B. Cell cycle analysis in control
cultures and in cultures induced to express CDKN1C. The data
represents the mean from three independent experiments and the
error bars represent the standard error of the mean.
Found at: doi:10.1371/journal.pone.0004482.s001 (0.21 MB TIF)
Figure S2 CDKN1C promoter methylation analysis. Allelic
bisulphite sequence analysis at the CDKN1C promoter in
uninduced (24HT) and in induced (+4HT) F22 and STMpc
cells. Open circles represent unmethylated cytosines and filled
circles represent methylated cytosines. No significant change in
allelic methylation was identified following the induction of
SMARCB1 protein expression.
Found at: doi:10.1371/journal.pone.0004482.s002 (0.52 MB TIF)
Figure S3 CDKN1C shows loss of imprinting in rhabdoid
tumor. CDKN1C imprinting in G401 and STM91-01 rhabdoid
tumor cell lines after 24, 48 and 72 hours in culture. CDKN1C
alleles in G401 cells differed by 24 bp and those in STM91-01
differed by 12 bp.
Found at: doi:10.1371/journal.pone.0004482.s003 (0.08 MB TIF)
Figure S4 Normal LIT1 methylation is maintained in rhabdoid
tumor. Methylation sensitive southern blotting at IC2 (LIT1) in
G401 and STM91-01 cells showing normal patterns of methyl-
ation, with methylated (4.2 kb) and unmethylated (2.7 kb) bands of
similar intensity.
Found at: doi:10.1371/journal.pone.0004482.s004 (0.06 MB TIF)
Figure S5 CDKN1C expression in clinical specimens of
rhabdoid tumor. A. Gene expression examined by RT-PCR in
clinical specimens of rhabdoid tumor. Tumor numbers match
those shown in Table 1. Relevant controls are shown: The -ve lane
represents the PCR negative control, the RNA -ve control lane
represents the negative control for reverse transcription and the
RT-ve control represents a control for genomic contamination
derived from the induced F22 sample. The positive control in the
far right lane shows the level of gene expression in F22 cells
expressing SMARCB1. Viability of the cDNA is shown by
amplification of the HPRT control gene. The lane for sample
3180 shows that little viable cDNA was obtained from this sample
as indicated by the negligible level of HPRT gene expression. B.
Immunohistochemical stains for CDKN1C expression. 1) placenta
positive control showing strong nuclear staining for CDKN1C, 2)
endometrium negative control, 3) placenta without primary
antibody 4) tumor section from case 1993 and 5) tumor section
from case 1938. 1993 and 1938 show some cytoplasmic staining
for CDKN1C but no nuclear staining.
Found at: doi:10.1371/journal.pone.0004482.s005 (0.71 MB TIF)
Table S1 Romidepsin reduces proliferation in rhabdoid tumor
cells. Table showing the percentage of cells in each cell cycle phase
after 72 hours treatment with 1 nM Romidepsin and in controls
containing 0.01% DMSO. The G401 data represent the mean
values from three independent experiments and the STM91-01
data represent the mean values from six independent experiments.
The error represents the standard error of the mean.
Found at: doi:10.1371/journal.pone.0004482.s006 (0.03 MB
DOC)
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